CPT® Code 90283

1. Indications

Immune globulin (IgIV) is indicated for various clinical situations where passive immunity is required. The following conditions may warrant the use of intravenous immune globulin:

• Immunodeficiency Disorders Patients with primary immunodeficiency disorders may require IgIV to provide necessary antibodies that their immune systems cannot produce effectively.
• Autoimmune Disorders Conditions such as autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura may be treated with IgIV to modulate the immune response.
• Infectious Diseases IgIV can be used in the treatment of certain infections, particularly in cases where the patient is at high risk for severe disease due to inadequate antibody production.
• Neurological Conditions Disorders like Guillain-Barré syndrome may be treated with IgIV to help reduce the severity and duration of symptoms.

2. Procedure

The administration of intravenous immune globulin (IgIV) involves several key procedural steps to ensure safety and efficacy. The following outlines the typical procedure:

• Step 1: Patient Assessment Prior to administration, a thorough assessment of the patient’s medical history and current health status is conducted. This includes evaluating any previous reactions to immune globulin products and determining the appropriate dosage based on the patient's weight and clinical condition.
• Step 2: Preparation of the Product The immune globulin product is prepared according to the manufacturer's instructions. This may involve thawing the product if it is frozen and ensuring that it is at room temperature before administration.
• Step 3: Venous Access A suitable intravenous access point is established, typically using a peripheral vein. In some cases, a central venous catheter may be used, especially for patients requiring long-term therapy or those with difficult venous access.
• Step 4: Administration The immune globulin is administered slowly through the intravenous line. The rate of infusion is carefully monitored and may be adjusted based on the patient's tolerance and any potential adverse reactions.
• Step 5: Monitoring Throughout the infusion, the patient is closely monitored for any signs of adverse reactions, such as fever, chills, or allergic responses. Vital signs are regularly checked to ensure the patient's stability during the procedure.

3. Post-Procedure

After the administration of intravenous immune globulin, patients are typically observed for a period to monitor for any delayed reactions. It is common for patients to experience mild side effects such as headache, fatigue, or mild fever, which usually resolve without intervention. Patients may be advised to hydrate adequately and report any unusual symptoms or reactions following the procedure. Follow-up appointments may be scheduled to assess the effectiveness of the treatment and to determine if additional doses are necessary based on the patient's ongoing clinical needs.